Newsroom

LOTTE BIOLOGICS (CEO James Park) announced on January 16 that it had presented at the "Asia-Pacific (APAC)" track of the J.P. Morgan Healthcare Conference (JPMHC).

The 2025 J.P. Morgan Healthcare Conference, now in its 43rd year, is the largest event in the pharmaceutical and biotechnology industries. Held in San Francisco, it runs from January 13 to 16 and brings together global pharmaceutical companies, biotech ventures, and healthcare investment professionals to discuss research and development (R&D), investment opportunities, and partnerships.

In his presentation, CEO James Park highlighted the successful transformation of the Syracuse Bio Campus in New York into a CDMO facility and outlined the vision for the Songdo Bio Campus. Notably, he unveiled the company’s innovative proprietary ADC platform, SoluFlex Link, and announced plans to collaborate with drug product partners in North America to provide a comprehensive one-stop ADC service. Through these initiatives, he expressed LOTTE BIOLOGICS' ambition to accelerate its growth in the global CDMO market.

SoluFlex Link is a proprietary ADC platform featuring a linker technology jointly developed by LOTTE BIOLOGICS and Kanaph Therapeutics, a biotech venture specializing in drug-conjugation technology.

SoluFlex Link overcomes the major challenge of instability in antibody-drug conjugate (ADC) therapeutics. Its flexible design supports compatibility with a wide range of antibodies and payloads, empowering ADC developers to innovate with diverse applications. Additionally, the platform is engineered to boost both production efficiency and therapeutic performance, positioning it as an ideal solution for next-generation ADC development and manufacturing.

Meanwhile, LOTTE BIOLOGICS' Syracuse Bio Campus received a flawless quality evaluation last year, with no findings reported during inspections by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and a routine audit by the U.S. Food and Drug Administration (FDA). CEO Park emphasized, "Even after the acquisition of the facility, we have maintained a high-quality production system, demonstrating our capabilities as a global CDMO company."

He explained that this served as an opportunity to demonstrate that LOTTE BIOLOGICS has established a global quality management system capable of producing high-quality biopharmaceuticals in compliance with international standards.

In addition, construction of Plant 1 at the Songdo Bio Campus began in March last year, with a total investment of $1 billion. The facility is currently under active development, aiming to commence full-scale commercial production by 2027.

CEO Park stated, "The Songdo Bio Campus Plant 1, scheduled for completion this year, will be a flexible, large-scale production facility equipped with an optimized operational system. By incorporating automated production processes and advanced manufacturing technologies, and leveraging the geographical advantages of Songdo and New York, we will maximize operational efficiency. We are committed to becoming a global company that not only ensures customer satisfaction but also achieves competitive quality standards."

Yu-Yeol Shin, Vice President and Head of Global Strategy at LOTTE BIOLOGICS, also attended the J.P. Morgan Conference for the first time since his appointment in late 2023. During the event, he participated in presentation sessions by companies such as Roche, Johnson & Johnson (J&J), and BMS to gain insights into pharmaceutical and biotechnology trends. Additionally, alongside CEO James Park, he actively engaged in business and partnership meetings with global pharmaceutical companies and potential clients, demonstrating a strong commitment to advancing LOTTE Group's new biopharmaceutical business.